Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition, in vitro and in silico studies

References

• Goud NS, Kumar P, Bharath RD. Recent developments of target-based benzimidazole derivatives as potential anticancer agents. Mini Rev Med Chem. 2020;20(17):1754–1766.
   Google Scholar
• Mostafa AS, Gomaa RM, Elmorsy MA. Design and synthesis of 2‐phenyl benzimidazole derivatives as VEGFR‐2 inhibitors with anti‐breast cancer activity. Chem Biol Drug Des. 2019;93(4):454–463.
   PubMed Web of Science ®Google Scholar
• Hamdi A, El-Shafey HW, Othman DI, El-Azab AS, AlSaif NA, Alaa A-M. Design, synthesis, antitumor, and VEGFR-2 inhibition activities of novel 4-anilino-2-vinyl-quinazolines: molecular modeling studies. Bioorg Chem. 2022;122:105710.
   PubMed Web of Science ®Google Scholar
• Singh H, Kinarivala N, Sharma S. Multi-targeting anticancer agents: rational approaches, synthetic routes and structure activity relationship. Anticancer Agents Med Chem. 2019;19(7):842–874.
   PubMed Web of Science ®Google Scholar
• Ibrahim HA, Refaat HM. Versatile mechanisms of 2-substituted benzimidazoles in targeted cancer therapy. Future J Pharm Sci. 2020;6(1):1–20.
   Web of Science ®Google Scholar
• Li Y, Tan C, Gao C, Zhang C, Luan X, Chen X, Liu H, Chen Y, Jiang Y. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. Bioorg Med Chem. 2011;19(15):4529–4535.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Leoni L. Bendamustine: mechanism of action and clinical data. Clin Adv Hematol Oncol. 2011;9(8 Suppl 19):1–11.
   Google Scholar
• Hasinoff BB, Wu X, Nitiss JL, Kanagasabai R, Yalowich JC. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol. 2012;84(12):1617–1626.
   PubMed Web of Science ®Google Scholar
• Ali AM, Tawfik SS, Mostafa AS, Massoud MAM. Benzimidazole-based protein kinase inhibitors: current perspectives in targeted cancer therapy. Chem Biol Drug Des. 2022;100(5):656–673.
   PubMed Web of Science ®Google Scholar
• Musolino A, Campone M, Neven P, Denduluri N, Barrios CH, Cortes J, Blackwell K, Soliman H, Kahan Z, Bonnefoi H, et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res. 2017;19(1):1–14.
   PubMedGoogle Scholar
• Nadhan R, Srinivas P, Pillai MR. RTKs in pathobiology of head and neck cancers. Adv Cancer Res. 2020;147:319–373.
   PubMed Web of Science ®Google Scholar
• Woei-A-Jin FJSH, Weijl NI, Burgmans MC, Fariña Sarasqueta A, van Wezel JT, Wasser MNJM, Coenraad MJ, Burggraaf J, Osanto S. Neoadjuvant treatment with angiogenesis-inhibitor dovitinib prior to local therapy in hepatocellular carcinoma: a phase II study. Oncologist. 2021;26(10):854–864.
   PubMed Web of Science ®Google Scholar
• Liu W-Q, Megale V, Borriello L, Leforban B, Montès M, Goldwaser E, Gresh N, Piquemal J-P, Hadj-Slimane R, Hermine O, et al. Synthesis and structure–activity relationship of non-peptidic antagonists of neuropilin-1 receptor. Bioorg Med Chem Lett. 2014;24(17):4254–4259.
   PubMed Web of Science ®Google Scholar
• McBride CM, Renhowe PA, Heise C, Jansen JM, Lapointe G, Ma S, Piñeda R, Vora J, Wiesmann M, Shafer CM, et al. Design and structure–activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006;16(13):3595–3599.
   PubMed Web of Science ®Google Scholar
• Pinar A, Yurdakul P, Yildiz I, Temiz-Arpaci O, Acan NL, Aki-Sener E, Yalcin I. Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors. Biochem Biophys Res Commun. 2004;317(2):670–674.
   PubMed Web of Science ®Google Scholar
• Nawareg NA, Mostafa AS, El-Messery SM, Nasr MN. New benzimidazole based hybrids: synthesis, molecular modeling study and anticancer evaluation as TopoII inhibitors. Bioorg Chem. 2022; 127:106038.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhao S-J, Liu Y. 1, 2, 3-Triazole-containing hybrids as potential anticancer agents: current developments, action mechanisms and structure-activity relationships. Eur J Med Chem. 2019;183:111700.
   PubMed Web of Science ®Google Scholar
• Alam MM. 1, 2, 3‐Triazole hybrids as anticancer agents: a review. Arch Pharm. 2022;355(1):2100158.
   PubMed Web of Science ®Google Scholar
• El-Sayed WA, Alminderej FM, Mounier MM, Nossier ES, Saleh SM, Kassem AF. Novel 1, 2, 3-triazole-coumarin hybrid glycosides and their tetrazolyl analogues: design, anticancer evaluation and molecular docking targeting EGFR, VEGFR-2 and CDK-2. Molecules. 2022;27(7):2047.
   PubMed Web of Science ®Google Scholar
• Wang D-P, Liu K-L, Li X-Y, Lu G-Q, Xue W-H, Qian X-H, Mohamed O K, Meng F-H. Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1, 2, 3-triazole scaffold. Eur J Med Chem. 2021;211:113083.
   PubMed Web of Science ®Google Scholar
• Abdel-Hafez GA, Mohamed A-MI, Youssef AF, Simons C, Aboraia AS. Synthesis, computational study and biological evaluation of 9-acridinyl and 1-coumarinyl-1, 2, 3-triazole-4-yl derivatives as topoisomerase II inhibitors. J Enzyme Inhib Med Chem. 2022;37(1):502–513.
   PubMed Web of Science ®Google Scholar
• Bistrović A, Krstulović L, Harej A, Grbčić P, Sedić M, Koštrun S, Pavelić SK, Bajić M, Raić-Malić S. Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer. Eur J Med Chem. 2018;143:1616–1634.
   PubMed Web of Science ®Google Scholar
• Sahay II, Ghalsasi PS. Synthesis of new 1, 2, 3-triazole linked benzimidazole molecules as anti-proliferative agents. Synth Commun. 2017;47(8):825–834.
   Web of Science ®Google Scholar
• Cai M, Hu J, Tian J-L, Yan H, Zheng C-G, Hu W-L. Novel hybrids from N-hydroxyarylamide and indole ring through click chemistry as histone deacetylase inhibitors with potent antitumor activities. Chin Chem Lett. 2015;26(6):675–680.
   Web of Science ®Google Scholar
• Nafie MS, Boraei AT. Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer. Bioorg Chem. 2022;122:105708.
   PubMed Web of Science ®Google Scholar
• Al-Hussain SA, Farghaly TA, Zaki ME, Abdulwahab HG, Al-Qurashi NT, Muhammad ZA. Discovery of novel indolyl-1, 2, 4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity. Bioorg Chem. 2020;105:104330.
   PubMed Web of Science ®Google Scholar
• Wang Z-J, Yang H-H, Tian L, Zhao W-G. Design, synthesis, and fungicidal activities of novel 5-methyl-1H-1, 2, 3-trizole-4-carboxyl amide analogues. Med Chem. 2016;12(3):290–295.
   PubMed Web of Science ®Google Scholar
• Theocharis A, Alexandrou N, Terzis A. Generation and dienophilic properties of 1‐benzyl‐1H‐1, 2, 3‐triazolo [4, 5‐d] pyridazine‐4, 7‐dione. J Heterocycl Chem. 1990;27(6):1741–1744.
   Web of Science ®Google Scholar
• Burres NS, Frigo A, Rasmussen RR, McAlpine JB. A colorimetric microassay for the detection of agents that interact with DNA. J Nat Prod. 1992;55(11):1582–1587.
   PubMed Web of Science ®Google Scholar
• Tolba MF, Esmat A, Al-Abd AM, Azab SS, Khalifa AE, Mosli HA, Abdel-Rahman SZ, Abdel-Naim AB. Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells. IUBMB Life. 2013;65(8):716–729.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.
   PubMed Web of Science ®Google Scholar
• Kumar R, Saneja A, Panda AK. An annexin V-FITC—propidium iodide-based method for detecting apoptosis in a non-small cell lung cancer cell line. Lung Cancer. 2021;2279:213–223.
   Google Scholar
• Selim NM, Elgazar AA, Abdel-Hamid NM, El-Magd MRA, Yasri A, Hefnawy HME, Sobeh M. Chrysophanol, physcion, hesperidin and curcumin modulate the gene expression of pro-inflammatory mediators induced by LPS in HepG2: in silico and molecular studies. Antioxidants. 2019;8(9):371.
   Web of Science ®Google Scholar
• Elsbaey M, Ibrahim MAA, Bar FA, Elgazar AA. Chemical constituents from coconut waste and their in silico evaluation as potential antiviral agents against SARS-CoV-2. S Afr J Bot. 2021;141:278–289.
   PubMed Web of Science ®Google Scholar
• Elgazar AA, Selim NM, Abdel-Hamid NM, El-Magd MA, El Hefnawy HM. Isolates from Alpinia officinarum Hance attenuate LPS-induced inflammation in HepG2: evidence from in silico and in vitro studies. Phytother Res. 2018;32(7):1273–1288.
   PubMed Web of Science ®Google Scholar
• Elgazar AA, Knany HR, Ali MS. Insights on the molecular mechanism of anti-inflammatory effect of formula from Islamic traditional medicine: an in-silico study. J Tradit Complement Med. 2019;9(4):353–363.
   PubMedGoogle Scholar
• Badria FA, Elgazar AA. Chapter 37 – revealing the molecular mechanism of Olea europaea L. in treatment of cataract. In: Preedy VR, Watson RR, editors. Olives and olive oil in health and disease prevention. 2nd ed. San Diego: Academic Press; 2021. p. 445–456.
   Google Scholar
• Othman DI, Hamdi A, Abdel-Aziz MM, Elfeky SM. Novel 2-arylthiazolidin-4-one-thiazole hybrids with potent activity against Mycobacterium tuberculosis. Bioorg Chem. 2022;124:105809.
   PubMed Web of Science ®Google Scholar
• Yao B-L, Mai Y-W, Chen S-B, Xie H-T, Yao P-F, Ou T-M, Tan J-H, Wang H-G, Li D, Huang S-L, et al. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors. Eur J Med Chem. 2015;92:540–553.
   PubMed Web of Science ®Google Scholar
• Hu C-X, Zuo Z-L, Xiong B, Ma J-G, Geng M-Y, Lin L-P, Jiang H-L, Ding J. Salvicine functions as novel Topoisomerase II poison by binding to ATP pocket. Mol Pharmacol. 2006;70(5):1593–1601.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Nishigaki N, Washio Y, Kano K, Harris PA, Sato H, Mori I, West RI, Shibahara M, Toyoda H, et al. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J Med Chem. 2007;50(18):4453–4470.
   PubMed Web of Science ®Google Scholar
• Verma N, Rai AK, Kaushik V, Brünnert D, Chahar KR, Pandey J, Goyal P. Identification of gefitinib off-targets using a structure-based systems biology approach; their validation with reverse docking and retrospective data mining. Sci Rep. 2016;6(1):1–12.
   PubMedGoogle Scholar
• Pires DE, Blundell TL, Ascher DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem. 2015;58(9):4066–4072.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.
   PubMed Web of Science ®Google Scholar
• Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986;89(2):271–277.
   PubMed Web of Science ®Google Scholar
• Hamdi A, Elhusseiny WM, Othman DIA, Haikal A, Bakheit AH, El-Azab AS, Al-Agamy MHM, Abdel-Aziz AA-M. Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethiazolidine-2,4-dione derivatives: histone deacetylases inhibitory activity and molecular docking study. Eur J Med Chem. 2022;244:114827.
   PubMed Web of Science ®Google Scholar
• Sofan MA, El‐Mekabaty A, Hasel AM, Said SB. Synthesis, cytotoxicity assessment and antioxidant activity of some new thiazol‐2‐yl carboxamides. J Heterocycl Chem. 2021;58(8):1645–1655.
   Web of Science ®Google Scholar
• El-Mawgoud HK, Fouda AM, El-Nassag MA, Elhenawy AA, Alshahrani MY, El-Agrody AM. Discovery of novel rigid analogs of 2-naphthol with potent anticancer activity through multi-target topoisomerase I & II and tyrosine kinase receptor EGFR & VEGFR-2 inhibition mechanism. Chem Biol Interact. 2022;355:109838.
   PubMed Web of Science ®Google Scholar
• Elimam DM, Elgazar AA, El-Senduny FF, El-Domany RA, Badria FA, Eldehna WM. Natural inspired piperine-based ureas and amides as novel antitumor agents towards breast cancer. J Enzyme Inhib Med Chem. 2022;37(1):39–50.
   PubMed Web of Science ®Google Scholar
• Böhm H-J. Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J Comput Aided Mol Des. 1998;12(4):309–323.
   PubMed Web of Science ®Google Scholar
• Kramer B, Rarey M, Lengauer T. Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking. Proteins. 1999;37(2):228–241.
   PubMed Web of Science ®Google Scholar
• Studio DJAISD, CA, USA. version 2.5; 2009.
   Google Scholar
• DeLano WL. Pymol: an open-source molecular graphics tool. CCP4 Newsl. Protein Crystallogr. 2002;40(1):82–92.
   Google Scholar